ExpreS2ion Biotech

Event Highlights
At both events, Mr. Frandsen highlighted:

• Phase I Clinical Progress: The first patients have been dosed in the ongoing Phase I trial of ES2B-C001 in HER2+ and HER2-low breast cancer. Up to 27 participants are expected, with interim data anticipated in mid-2026.

• Pipeline Breadth: ExpreS2ion continues to advance multiple vaccine programs, including 11 malaria vaccine trials with the University of Oxford and consortium-driven influenza and Nipah virus vaccine projects.

• Market Opportunity: ES2B-C001 addresses a global market for HER2-positive breast cancer therapies estimated at over USD 13 billion annually.

• Financial Position: The Company reported strong growth in CRO and grant revenues (+61% YoY in H1 2025) while maintaining disciplined cost control.

• TO 11 Warrants (ProHearings presentation): The Company also referred to the TO 11 warrants during its ProHearings presentation. Full details, including terms, timetable, and documentation, are available on ExpreS2ion’s investor website at https://investor.expres2ionbio.com/rights-issue-2024/.

The Økonomisk Ugebrev and ProHearings sessions also included live Q&A discussions, giving investors the opportunity to ask about clinical progress, business development, and financial outlook.

The full presentation decks used during the conferences are available on the Company’s investor site here. Video recordings of both events, including the Q&A sessions, are also available at the same link.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB